| At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of its potentially breakthrough mRNA innovation. Then the coronavirus pandemic hit, Moderna redirected its technology, and by year's end it delivered one of the world's first and most effective Covid-19 vaccines. Biotech, and the venture capital community that fuels it, would never be the same. |
|
| |
Moderna, the Vaccine, and the Business Gamble That Changed the World
with Peter Loftus and Scott Berinato | |
| 17 October 2022, 13.00 GMT / 17.30 IST | |
| | |
At the start of 2020, Moderna was a waning biotech unicorn, still years away from delivering its first product despite a decade of development of its potentially breakthrough mRNA innovation. Then the coronavirus pandemic hit, Moderna redirected its technology, and by year's end it delivered one of the world's first and most effective Covid-19 vaccines. Biotech, and the venture capital community that fuels it, would never be the same. In his new book The Messenger, Wall Street Journal's Peter Loftus applies 30 years of reporting—including 17 years on pharma and biotech—and deep access to all of the major players, to tell the behind-the-scenes tale of Moderna from its humble start at a casual lunch, through its heady startup days, into the heart of the pandemic and beyond. On October 17th, Peter and his HBR editor Scott Berinato will join us to discuss the story of Moderna and all the surprising developments since the book published, from new drug trials to lawsuits. We hope you can join us. "The Messenger is an engagingly pacy yet detailed narrative that traces the scientific origins of the Moderna story through the various dramas that led to the licensing of the vaccine." — Irish Times Register to confirm your place. The event is free to HBR subscribers and followers. Click here to learn more about HBR and how to subscribe. Attendees based in India can purchase a discounted copy of The Messenger at this link. Please apply discount code readhbr | |
| |
| Peter Loftus writes about the pharmaceutical industry and health care for the Wall Street Journal. Based in Philadelphia, he covers large drugmakers, biotech firms, and the latest developments in drug research and innovation. He has followed Moderna and the wider chase for a Covid-19 vaccine from their start. He is part of a Journal reporting team that was a finalist for the Pulitzer Prize. | |
| |
| You are receiving this because you registered at hbr.org to receive Live Events emails, or you provided us with your email address. If you prefer not to receive Live Events emails, please unsubscribe. You may also Manage Email Preferences, view our Privacy Policy, or Contact Us. To ensure email delivery, add noreply@a.email.hbr.org to your address book, contacts, or safe sender list.
Harvard Business Publishing
20 Guest St., Suite 700
Brighton, MA 02135 Copyright © 2022 Harvard Business School Publishing.
All rights reserved. | |
